SPOTLIGHT -
Emerging Therapies and Unmet Needs in MS
Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.
Role of Oral BTKi in MS Management
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of the different types of Bruton tyrosine kinase inhibitors (BTKi) in management of MS.
Sequencing of Therapies in MS
Experts in neurology highlight the factors they consider when switching treatments for a patient with MS.
Use of Cladribine in MS Treatment
Ahmed Zayed Obeidat MD, PhD, and Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, discuss the use of oral cladribine in the treatment of MS.
Efficacy and Safety of Oral Therapies in MS
Experts in neurology present long-term efficacy and safety data of oral DMTs in the treatment of MS and share their perspective on the real-world significance.
DMT Adherence and Routes of Administration in MS
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.
Risk of MS Disease Progression and Complementary Diagnostic Tools
Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.
Approaching Treatment for MS Management
Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.
Disease-Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.
